See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
GSK PLC Sponsored ADR (GSK) - free report >>
Johnson & Johnson (JNJ) - free report >>
Gilead Sciences, Inc. (GILD) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK PLC Sponsored ADR (GSK) - free report >>
Johnson & Johnson (JNJ) - free report >>
Gilead Sciences, Inc. (GILD) - free report >>
These 6 Drug Companies are Testing a Coronavirus Vaccine
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Biotech giant Gilead Sciences (GILD - Free Report) is planning to administer its remdesivir drug to patients next month. Remdesivir is an experimental drug that has been used to treat Ebola. The World Health Organization (WHO) believes it may be the best chance to effectively treat the coronavirus.
Novavax (NVAX - Free Report) and Moderna (MRNA - Free Report) are also working on vaccines, and both companies expect to begin phase 1 studies soon. Drugmaker Sanofi (SNY - Free Report) recently announced plans to develop a vaccine; it said it will leverage previous work for a SARS pre-clinical vaccine. Other large drug makers like GlaxoSmithKline (GSK - Free Report) and Johnson & Johnson (JNJ - Free Report) are working on vaccines as well.
Scientists are hoping to cut the time it takes to develop a vaccine in half—which used to take years, since the virus had to be grown in a lab—with a new tool that builds a vaccine based on a virus’ genetic sequence. Researchers are hoping to have a viable preventive by this fall.
We are reissuing this article to correct a mistake. The original article, issued February 28, 2020, should no longer be relied upon.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>